Lapatinib 39 and onvansertib 40 are PLK1 kinase inhibitors that improve the cisplatin response via inducing pyroptosis in ESCC and others through caspase-3/GSDME/Bax activation [22, 147–151]. This evidence concerns the gene GSDME and esophageal squamous cell carcinoma.